Mizuho Securities Cuts Price Target on CareDx (CDNA) to $8 Following Allenex Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Piper Jaffray Remains Bullish on CareDx (CDNA) Following Presentation of AlloSure Performance
June 14, 2016 9:07 AM EDTPiper Jaffray maintained an Overweight rating and $6.00 price target on CareDx, Inc (NASDAQ: CDNA) following the company's presentation of its DART clinical trial. Piper Jaffray would describe DART's first look data as solid with AlloSure a significantly better predictor of kidney health than creatinine.
Analyst William Quirk... More
Unusual 11 Mid-Day Movers 6/13: (EBIO) (LNKD) (PWE) Higher; (MRNS) (GBR) (ARGS) Lower
June 13, 2016 1:01 PM EDTMarinus Pharmaceuticals, Inc. (Nasdaq: MRNS) 69.6% LOWER; announced top-line results from its Phase 3 clinical trial in adults with drug-resistant focal onset seizures. In this trial, ganaxolone did not meet the primary endpoint of demonstrating a statistically significant difference from placebo. Consistent with previously conducted studies, ganaxolone was generally safe and well tolerated. Marinus plans to discontinue its program in adult focal onset seizures and focus its efforts on advancing ganaxolone in status epilepticus and pediatric orphan indications.
